Double Creation News
On August 20, 2022, in the 11th China Innovation and Entrepreneurship Competition (Guangdong Region), Wu Guangming, Chairman of MingCeler Biology, advanced to the final round of Guangdong Province with his project, "A rapid generation of transgenic mouse models", a world-leading breakthrough technology.
It is reported that this competition after the preliminary screening, more than 5000 enterprises, and more than 370 enterprises into the final round, of which a total of 24 companies in the life science field startups group were shortlisted for the final round. MingCeler won third place in the rehearsal startup group and looks forward to the next best performance in the Guangdong Province finals.
Spotlight on the scene
In order to implement the spirit of the Sixth Plenary Session of the 19th CPC Central Committee and the Central Economic Work Conference, and to further implement the innovation-driven development strategy, the competition focuses on "Innovation Leads, Entrepreneurship Builds Dreams", and this is the first time for MingCeler Biology to participate in the dual innovation competition. The founder of the company, Wu Guangming, has been working in world-renowned research institutions in the United States and Germany since 1995, and his name is permanently displayed in the Deutsches Museum in Germany due to his outstanding contributions to the field of developmental biology. In early 2020, when COVID-19 was a severe threat to public health and safety, Wu Guangming used his unique "tetraploid compensation technology" to produce and deliver ACE2, a humanized mouse model of the new crown vaccine and drug development, to several research institutions in bulk within 2 months. He was awarded the title "Advanced Individual in the Fight against Neoplastic Pneumonia" in Guangdong Province for his outstanding contribution to the fight against Neoplastic pneumonia.
The project "Rapid Preparation Technology for New Generation of Animal Models" is based on Wu Guangming's years of research accumulation, his unique optimized "tetraploid compensation technology", with independent patents and the world's cutting-edge operation level, and the establishment of an engineering system. In January 2022, researcher Guangming Wu established Guangzhou MingCeler Biotechnology Co. The company is focused on the transformation of tetraploid compensation technology, developing a new generation of mouse modeling technology with industry disruption, breaking the current technical barriers in the mouse model preparation industry, achieving the goals of shortening the modeling cycle, rapid targeted customization, reducing production costs, and increasing the production efficiency of highly difficult and complex models.
Guangzhou MingCeler Biotech Co., Ltd(referred to as MingCeler) specializes in the rapid and personalized customization of various types of genetically modified model mice, with a leading position in the world in the modeling cycle, which can be as short as 2 months, providing pure-compatible model mice and professional genetic strategy consulting for customers. We are committed to providing cutting-edge, high-end, rapid, and excellent model biotechnology services and resources to innovative global pharmaceutical companies, vaccine companies, universities, research institutes, hospitals, and other health-related research teams.
Core technology advantages
Super high efficiency: Our unique tetraploid compensation technology solution can significantly increase the birth rate of mice from the highest 1-5% already reported internationally to 30-60%, completely solving the industrialization problem of tetraploid compensation technology.
Ultra-fast: complete individual mice can be prepared directly from mouse embryonic stem cells, bypassing the time-consuming breeding steps of conventional technology, and the preparation time can be shortened to less than 2 months with a high success rate.
Multiple choices: multiple strains to choose from, inbred, distant, and hybrid; provides multi-locus, long fragment complex models.
Post time: Aug-02-2023